Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

757 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
Stenner-Liewen F, Grünwald V, Greil R, Porta C. Stenner-Liewen F, et al. Among authors: porta c. Expert Rev Anticancer Ther. 2013 Sep;13(9):1021-33. doi: 10.1586/14737140.2013.833684. Epub 2013 Sep 12. Expert Rev Anticancer Ther. 2013. PMID: 24024788 Review.
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, Riccardi A. Porta C, et al. Cancer. 2004 May 15;100(10):2132-8. doi: 10.1002/cncr.20226. Cancer. 2004. PMID: 15139055 Clinical Trial.
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Sartore-Bianchi A, Soriani A, Mattioni R, Vaglio A, Buzio C, Porta C. Sartore-Bianchi A, et al. Among authors: porta c. Oncol Rep. 2004 Oct;12(4):855-9. Oncol Rep. 2004. PMID: 15375512
Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C. Porta C. Expert Rev Anticancer Ther. 2006 Jan;6(1):141-52. doi: 10.1586/14737140.6.1.141. Expert Rev Anticancer Ther. 2006. PMID: 16375651 Review.
Sigmoid colon metastasis from sarcomatoid renal cell carcinoma.
Invernizzi R, Bencardino K, Porta C, Vercelli A, Viglio A, Manzoni M, Sagrada P, Danova M. Invernizzi R, et al. Among authors: porta c. Tumori. 2006 May-Jun;92(3):246-8. Tumori. 2006. PMID: 16869245
Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.
Porta C, Bonomi L, Lillaz B, Paglino C, Rovati B, Imarisio I, Morbini P, Villa C, Danova M, Mensi M, Rovereto B. Porta C, et al. Anticancer Res. 2007 Jan-Feb;27(1A):165-73. Anticancer Res. 2007. PMID: 17352228
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Motzer RJ, et al. Among authors: porta c. Lancet. 2008 Aug 9;372(9637):449-56. doi: 10.1016/S0140-6736(08)61039-9. Epub 2008 Jul 22. Lancet. 2008. PMID: 18653228 Clinical Trial.
Tolerability of first-line therapy for metastatic renal cell carcinoma.
Porta C, Szczylik C. Porta C, et al. Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Cancer Treat Rev. 2009. PMID: 19249157 Review.
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Gore ME, et al. Among authors: porta c. Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15. Lancet Oncol. 2009. PMID: 19615940 Clinical Trial.
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
Porta C, Figlin RA. Porta C, et al. J Urol. 2009 Dec;182(6):2569-77. doi: 10.1016/j.juro.2009.08.085. J Urol. 2009. PMID: 19836781 Review.
757 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page